University of Michigan Rogel Cancer Center
This phase II trial tests how well ivonescimab before surgery works in treating patients with stage II-IV head and neck cancer that can be removed by surgery (resectable). Ivonescimab is a bispecific monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A bispecific monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).
Inclusion Criteria: * At least 18 years of age * PD-L1 combined positive score (CPS) \>= 1 * Histologically documented advanced stage mucosal HNSCC (stage II-IV), for which surgery would be recommended in routine clinical practice * Primary tumor is amenable to fresh biopsy or availability of archival fresh frozen primary tissue * Eastern Cooperative Oncology Group (ECOG) 0-1 * Absolute neutrophil count \> 1500 cells/uL * Platelet count \>= 100,000/uL * Hemoglobin \>= 9.0 g/dL (without transfusion within 14 days prior to cycle 1, day 1) * Total bilirubin =\< 1.5 x institutional upper limit of…
Undergo biopsy
Undergo blood sample collection
Undergo PET-CT and CT scan
Given IV
Undergo MRI
Undergo PET-CT scan
Undergo surgical dissection
Arctuva estimate
Verify or correct the compensation shown for this listing.